KEGG   DRUG: Moxetumomab pasudotoxHelp
Entry
D09932                      Drug                                   

Name
Moxetumomab pasudotox (USAN/INN);
Moxetumomab pasudotox-tdfk;
Lumoxiti (TN)
Product
Formula
C2804H4339N783O870S14
Exact mass
63348.5445
Mol weight
63387.0886
Remark
Product: D09932<US>
Efficacy
Antineoplastic, Anti-CD22 antibody
  Disease
Hairy-cell leukemia [DS:H00006]
Comment
Antibody-drug conjugate
Target
CD22 [HSA:933] [KO:K06467]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   SIGLEC family
    CD22
     D09932  Moxetumomab pasudotox (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09932
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09932
BRITE hierarchy
Other DBs
CAS: 1020748-57-5
PubChem: 135626666
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system